Grant McArthur
Overview
Explore the profile of Grant McArthur including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
9113
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hauschild A, Garbe C, Ascierto P, Demidov L, Dreno B, Dummer R, et al.
Lancet Oncol
. 2025 Jan;
26(1):12-14.
PMID: 39756440
No abstract available.
2.
Robb T, Liu Y, Woodhouse B, Windahl C, Hurley D, McArthur G, et al.
NPJ Digit Med
. 2024 Sep;
7(1):261.
PMID: 39343807
We introduce a proof-of-concept extended reality (XR) environment for discussing cancer, presenting genomic information from multiple tumour sites in the context of 3D tumour models generated from CT scans. This...
3.
Smith K, OHaire S, Markman B, Gan H, OByrne K, Millward M, et al.
JCO Precis Oncol
. 2024 Aug;
8:e2300247.
PMID: 39208376
Purpose: Despite increasing evidence of benefit supporting complex genomic sequencing (CGS) in personalizing cancer therapy, its widespread uptake remains limited. Methods: This mixed-methods, prospective cross-institutional demonstration study was designed to...
4.
Lai-Kwon J, Woodward-Kron R, Seignior D, Allen L, McArthur G, Barrett M, et al.
BMC Med Educ
. 2024 Jul;
24(1):734.
PMID: 38977978
Background: Evaluations of continuing professional development programs typically focus on short-term knowledge and skill acquisition. There is a need for more comprehensive program evaluation methods that assess a broader range...
5.
Ertl C, Ruf T, Mentzer D, Kong M, Kramer R, von Bergwelt-Baildon M, et al.
Eur J Cancer
. 2024 Jan;
199:113505.
PMID: 38262306
Background: Immunotherapies such as immune checkpoint inhibitors (ICI) are effective in multiple tumor entities but induce a plethora of side effects. Comprehensive real-world analyses are essential to identify new signals,...
6.
Lai-Kwon J, Dushyanthen S, Seignior D, Barrett M, Buisman-Pijlman F, Buntine A, et al.
BMC Med Educ
. 2023 Jul;
23(1):544.
PMID: 37525150
Background: Improving oncology-specific knowledge and skills of healthcare professionals is critical for improving the outcomes of people with cancer. Many current postgraduate education offerings may be inaccessible to busy professionals,...
7.
Goldinger S, Buder-Bakhaya K, Lo S, Forschner A, McKean M, Zimmer L, et al.
Eur J Cancer
. 2021 Dec;
162:22-33.
PMID: 34952480
Introduction: Despite remarkably improved outcomes with immune checkpoint inhibition, many patients with metastatic melanoma will eventually require further therapy. Chemotherapy has limited activity when used first-line but can alter the...
8.
Wolchok J, Chiarion-Sileni V, Gonzalez R, Grob J, Rutkowski P, Lao C, et al.
J Clin Oncol
. 2021 Nov;
40(2):127-137.
PMID: 34818112
Purpose: In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolumab alone versus ipilimumab. Here, we report 6.5-year efficacy and safety...
9.
Te Marvelde L, Wolfe R, McArthur G, Blake L, Evans S
Med J Aust
. 2021 Feb;
214(6):281-283.
PMID: 33624884
No abstract available.
10.
Degeling K, Baxter N, Emery J, Jenkins M, Franchini F, Gibbs P, et al.
Asia Pac J Clin Oncol
. 2021 Feb;
17(4):359-367.
PMID: 33567163
Aim: Decreased cancer incidence and reported changes to clinical management indicate that the COVID-19 pandemic has delayed cancer diagnosis and treatment. This study aimed to develop and apply a flexible...